secwatch.observer — SEC 8-K summary
======================================

Issuer:     MBX Biosciences, Inc. (MBX)
CIK:        0001776111
Form:       8-K
Filed at:   2025-09-04T23:59:59+00:00
Accession:  0001776111-25-000007
Event type: other_material
Sentiment:  neutral
Materiality: 0.35
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

MBX Biosciences doses first participant in Phase 1 trial of obesity drug MBX 4291
--------------------------------------------------------------------------------

- Phase 1 trial is randomized, double-blind, placebo-controlled; Part A: 5 SAD cohorts (8 each, 3:1 randomization).
- Part B: 3 MAD cohorts (4 weekly doses, 8 each, 3:1 randomization); plus optional 12-week MAD cohorts (30 each, 2:1).
- Topline results anticipated in 2027; preclinical data support once-monthly dosing and improved GI tolerability.
- MBX 4291 is a long-acting GLP-1/GIP co-agonist prodrug for obesity, designed for best-in-class weight loss.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1776111/000177611125000007/0001776111-25-000007-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1776111/000177611125000007/mbx-20250904.htm
  HTML page:      https://secwatch.observer/filing/0001776111-25-000007

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer